These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An inactivated oil-emulsion fowl Adenovirus serotype 4 vaccine provides broad cross-protection against various serotypes of fowl Adenovirus.
    Author: Kim MS, Lim TH, Lee DH, Youn HN, Yuk SS, Kim BY, Choi SW, Jung CH, Han JH, Song CS.
    Journal: Vaccine; 2014 Jun 12; 32(28):3564-8. PubMed ID: 24662704.
    Abstract:
    The number of clinical cases of inclusion body hepatitis (IBH) and hydropericardium-hepatitis syndrome (HHS) has been increasing, resulting in considerable economic losses in many countries. Currently, only fowl Adenovirus (FAdV) serotype 4 (FAdV-4) has been reported as the causative agent of HHS, whereas IBH can be caused by all 12 serotypes of FAdV. For protection against HHS, various live and killed FAdV serotype 4 vaccines have been developed. However, there is a concern whether these vaccines composed of FAdV-4 alone could provide protection against IBH, which is caused by other serotypes of virulent FAdVs. To date, there have been no reports evaluating the protective efficacy of the FAdV-4 vaccine against other serotypes of FAdV. Thus, we investigated the cross-protection efficacy of an inactivated oil-emulsion FAdV-4 vaccine against various serotypes of FAdV field isolates. Our study demonstrated that the inactivated oil-emulsion FAdV-4 vaccine could provide broad cross-protection against various serotypes of FAdV in not only vaccinated birds, but also the progenies of vaccinated breeder. Therefore, we conclude that the inactivated oil-emulsion FAdV-4 vaccine could be effective in preventing the spread of various other serotypes of FAdV as well as FAdV-4 infection in the poultry industry.
    [Abstract] [Full Text] [Related] [New Search]